Introduction
============

It is by now well known that the Women's Health Initiative found no benefit of estrogen therapy on cognitive function for post-menopausal women (for reviews, see Anderson et al., [@B5]; Espeland et al., [@B27]). However, a recent evidence-based statement indicates that estrogen therapy may be effective, but it must be initiated not after menopause but during the perimenopausal period (North American Menopause, [@B56]). The lack of unequivocal benefit of estrogen therapy on cognitive function is surprising, considering that estrogen receptors α and β (ERα and ERβ) are found throughout the hippocampus and cortex, the two brain regions most implicated in Alzheimer Disease (AD; Shughrue and Merchenthaler, [@B68]), and that estrogen is effective in lowering brain amyloid-β (Aβ) levels in ovariectomized transgenic mice that overexpress Aβ (e.g., Levin-Allerhand et al., [@B48]; Carroll et al., [@B12]). Many other factors are also involved in the pathogenesis of AD, and it is possible that the failure to take them into account has obscured the potential benefit of estrogen therapy. The purpose of this computational modeling study is to begin to account for the many factors in addition to estrogen that participate in the regulation of Aβ, and to explore ways in which estrogen therapy might be used more effectively in AD treatment, perhaps by administering estrogen in conjunction with other agents. The modeling results can be considered as predictions concerning the effects of administration of estrogen, ER agonists, and other agents, alone or in combination, on the level of Aβ. Verification of these predictions in mouse models of AD would suggest potential new avenues for the development of pharmacological strategies for AD treatment.

It has been recognized for over a decade that neurodegenerative diseases such as AD are highly complex and multifactorial (e.g., Jellinger, [@B39]). Meanwhile, the database of experimental findings on AD grows at an accelerating pace. The sheer size and complexity of the AD database poses a barrier to understanding this disease. Computational methods are needed to represent the many interactions that are involved in AD and to simulate and analyze them in order to gain insight into the disorder, and to generate experimentally testable hypotheses that are also relevant to possible treatments. Recently, powerful computational methods for simulating and analyzing complex systems have been imported from computer science into biology (for reviews, see Hlavacek et al., [@B36]; Fisher and Henzinger, [@B30]). These methods, known as formal methods in computer science, are implemented using declarative programming languages.

Computationally modeling a system using declarative programming permits not only simulation but also analysis of the system being modeled (Huth and Ryan, [@B38]). The analysis capability is essential for reasoning about complex neurodegenerative disorders such as AD. The declarative programming language used for the simulations and analyses presented here is known as Maude (Clavel et al., [@B16]). Maude has been previously used for modeling biological systems (Eker et al., [@B25]; Talcott, [@B75]), and Maude has been recently used to model some of the molecular and cellular interactions that underlie Aβ regulation (Anastasio, [@B4]). That model is extended here to include many of the contributions that estrogen makes to Aβ regulation, and the estrogen-Aβ model will provide new insights into the multifactorial role of this hormone in preventing AD.

The estrogen-Aβ model will also be used to explore the possible benefits of combining other compounds with estrogen, or with ER agonists, to enhance their ability to reduce Aβ levels. In recognition of AD multifactoriality, some recent experimental studies have focused on single molecules that act as multitarget drugs (Bajda et al., [@B6]; Leon and Marco-Contelles, [@B46]). Whether the treatment involves one drug with multiple targets or multiple drugs with single targets, a consensus is emerging that preventing or treating a multifactorial disease such as AD will require a multitarget approach. The computational simulation and analysis methods presented here are ideal for generating new hypotheses on multitarget therapies for AD.

Materials and Methods {#s3}
=====================

The model is based on the "amyloid hypothesis," according to which AD results from the buildup beyond normative levels of the Aβ peptide (Hardy and Selkoe, [@B32]). The model concerns the regulation of Aβ and the transition from the normative to the pathological state, rather than the state of advanced AD pathology in which Aβ levels have been chronically elevated. Although several possible triggers for Aβ buildup have been proposed, the model incorporates the subsidiary hypothesis that incipient cerebrovascular disease (CVD) can cause changes on the molecular level that dysregulate Aβ and lead to its buildup (Scheibel et al., [@B64]; de la Torre, [@B19]). The effects of estrogen on Aβ regulation are analyzed with and without the dysregulating effects of CVD. In order to focus attention on the effects of estrogen on Aβ regulation, any protection from CVD due to estrogen is disregarded.

Biological background: Basic Aβ regulation
------------------------------------------

The Aβ peptide occurs in two lengths, Aβ~40~ and Aβ~42~, and both are toxic after they self-aggregate (Walsh and Selkoe, [@B85]; Di Carlo, [@B24]). For simplicity here, no distinction will be made between Aβ~40~ and Aβ~42~. The Aβ peptide is produced via cleavage of amyloid precursor protein (APP) by β-secretase (BACE1 or simply BACE; Vassar et al., [@B82], [@B83]) followed by γ-secretase (Borchelt et al., [@B10]; De Strooper, [@B20]). Another enzyme, α-secretase (Esch et al., [@B26]; Sisodia, [@B69]; Vingtdeux and Marambaud, [@B84]) competes with BACE for APP as its substrate. Cleavage of APP by α-secretase precludes cleavage of APP by BACE, so that cleavage of APP by α-secretase precludes Aβ formation. The three secretases, α, β, and γ, and their substrate, APP, are all membrane proteins.

The γ-secretase enzyme occurs as a complex composed of presenilin-1 (PS1), presenilin enhancer-2 (PEN2), nicastrin, and anterior pharynx-defective phenotype-1 (APH1; De Strooper, [@B20]). APH1 is not represented in the model because little is known of its regulation, but it is assumed to be present constitutively. Regulation of the other γ-secretase components is represented in the model. Expression of PS1 and PEN2 is upregulated by c-Jun, which is phosphorylated by c-Jun N-terminal kinase (JNK) after JNK is activated by oxidative stress (OS; Tamagno et al., [@B76]). In contrast, the extracellular signal regulated mitogen-activated kinase (ERK) phosphorylates nicastrin and thereby downgrades its activity (Kim et al., [@B42]). Buildup of Aβ leads to OS and ERK activation (Bodles and Barger, [@B9]; Kim et al., [@B42]). Thus, Aβ exerts opposing influences on γ-secretase because it upregulates two of its components (PS1 and PEN2 via OS, JNK, and c-Jun) but downgrades one of its components (nicastrin via ERK; Tamagno et al., [@B77]).

Both normative and pathological mechanisms regulate BACE. Two normative loops operate at the RNA level. In one, Aβ upregulates expression of the BACE antisense transcript (BACEASRNA), which stabilizes the BACE message (BACEmRNA), and thereby increases BACE protein expression (Faghihi et al., [@B29]). In another, Aβ downregulates expression of micro-RNA-107 (BACEmiRNA), which binds to a micro-RNA recognition element on BACEmRNA and reduces its translation to BACE (Wang et al., [@B87]). Both of these mechanisms increase BACE protein expression, because Aβ upregulates BACEASRNA, which increases BACE expression, while Aβ downregulates BACEmiRNA, which decreases BACE expression. Note that the second loop achieves increase via decrease of decrease. In general, any pathway or loop with an even number of decreases will produce increase, just as in algebra, multiplication of an even number of negatives yields a positive.

Two pathological loops regulating Aβ are positive because they involve even numbers of negative interactions. In the first, Aβ buildup leads to activation of cytokines (Udan et al., [@B79]; Bulgarelli et al., [@B11]), which downregulate expression of the message for peroxisome proliferator-activated receptor γ (PPARmRNA), but PPAR downregulates BACEmRNA (Sastre et al., [@B62]). Thus, Aβ drives its own buildup by activating cytokines, which suppress PPAR, which is a suppressor of BACE, which is the enzyme most responsible for Aβ production. Non-steroidal anti-inflammatory drugs (NSAIDs) can diminish the effects on Aβ buildup of this positive feedback loop by upregulating PPAR (Sastre et al., [@B62]).

The second pathological positive feedback loop involves four negative interactions. Buildup of Aβ causing OS leads to release from mitochondria of second mitochondrial-derived activator of caspase (Smac; Yin et al., [@B91]). Smac binds to and inhibits XIAP, a member of the inhibitor of apoptosis protein (IAP) family of proteins. IAPs inhibit caspase-9. Thus, release of Smac activates caspase-9 by inhibiting IAPs, thereby releasing caspase-9 from IAP inhibition. Activation of caspase-9 leads to activation of caspase-3 leading to apoptosis (Estaquier et al., [@B28]). Another function of caspase-3 is to cleave, and thereby inactivate, Golgi-localized γ-ear-containing ADP-ribosylation-factor binding protein (GGA3; ADP is adenosine di-phosphate; Tesco et al., [@B78]). Because GGA3 participates in BACE degradation, caspase-3 activation increases BACE availability by suppressing its degradation. Thus, around a positive feedback loop involving OS and the apoptotic pathway, Aβ drives its own accumulation through two double negatives, the result of which is to reduce BACE degradation. The degradation-reducing effects of this loop can be partly diminished by seladin-1, which decreases caspase-3 activity (Sarajärvi et al., [@B61]), but BACE degradation can be augmented by sorting nexin 6 (SNX6; Muhammad et al., [@B54]; Small, [@B70]).

Less is known of the regulation of α-secretase than of γ- or β-secretase (BACE), but the A disintegrin and metalloprotease 10 and 17 (ADAM10 and ADAM17) family members likely perform the α-secretase function (Allinson et al., [@B2]). Either or both of ADAM10 and ADAM17 may be regulated by protein kinase C (PKC).

The cerebrovascular insufficiency due to CVD causes both hypoxia (reduction in oxygen level) and ischemia (reduction in blood flow), and can alter Aβ processing by both routes. The reduction in oxygen level activates hypoxia inducible factor-1-α (HIF1α or simply HIF), which upregulates BACEmRNA transcription (Zhang et al., [@B94]; Guglielmotto et al., [@B31]). The energy deprivation due to ischemia activates pancreatic endoplasmic reticulum eIF2-α kinase (PERK), which phosphorylates eukaryotic initiation factor-2-α (eIF2α or simply eIF2), which in turn de-represses a regulatory element on BACEmRNA and increases BACE protein translation (O'Connor et al., [@B57]). The increases in BACE protein due to CVD lead to increases in Aβ.

The low-density lipoprotein receptor-related protein (LRP) is involved in multiple but conflicting ways in Aβ processing. It increases Aβ by binding APP and then making APP more available to BACE and γ-secretase (Ulery et al., [@B80]; Yoon et al., [@B92]; Lakshmana et al., [@B45]). In contrast, LRP decreases Aβ by binding apolipoprotein E (apoE), whereupon the apoE, along with the Aβ it has bound, is internalized and the Aβ is degraded in the lysosome (Strittmatter et al., [@B73]; Manelli et al., [@B51]). Also, LRP decreases Aβ by binding it and transcytosing it from the brain into the peripheral circulation over the brain epithelial cells (BECs) that compose the blood-brain barrier (Shibata et al., [@B66]; Deane et al., [@B23]). In its transcytotic role LRP works with P-glycoprotein (Pgp), which transcytoses Aβ out of the brain (Cirrito et al., [@B14]; Kuhnke et al., [@B43]), but it works against the receptor for advanced glycation end products (RAGE), which transcytoses Aβ in the opposite direction, into the brain (Deane et al., [@B22]).

Other molecular mechanisms that regulate Aβ include reticulon-3 (RTN3) and heparan sulfate, both of which bind BACE and inhibit Aβ production (Scholefield et al., [@B65]; He et al., [@B33]; Kume et al., [@B44]). Receptor-associated protein (RAP) binds Aβ and causes its internalization and degradation (Kanekiyo and Bu, [@B40]). Enzymes that degrade Aβ include neprilysin (NEP), insulin degrading enzyme (IDE), and angiotensin-converting enzyme (ACE; Hu et al., [@B37]; Sudoh et al., [@B74]; Kanemitsu et al., [@B41]; Hiltunen et al., [@B35]). The mechanisms outlined in the subsection are included in a previous model of Aβ regulation (Anastasio, [@B4]). They represent many of the basic mechanisms of Aβ regulation that have been described by recent research.

Biological background: Influences of estrogen
---------------------------------------------

The main focus of the analysis described here is on the contribution of estrogen to Aβ regulation. More specifically, the model represents not fewer than nine different ways in which estrogen lowers Aβ levels. The influences of estrogen involve classical changes in protein expression levels as well as direct effects of estrogen on cell signaling. These influences are represented in the model in the context of the basic mechanisms of Aβ regulation outlined in the previous subsection. As for the basic mechanisms, the estrogen-mediated effects outlined in this subsection include many of those that have been described by recent research. Although most animal-based and *in vitro* experiments employ 17-β-estradiol rather than other forms of estrogen, the generic term estrogen will be used here for simplicity.

Estrogen binds and activates both PKCα and PKCδ (Alzamora et al., [@B3]). This binding and activation are direct and occur independently of estrogen binding to estrogen receptors. PKCα, but not PKCδ, shifts APP processing from BACE to α-secretase *in vitro* (Cisse et al., [@B15]). Such a shift from away from the amyloidogenic pathway decreases Aβ levels. These effects were due to activation of ADAM10 and/or ADAM17 by PKCα, and were not due to activation of ERK, which activates ADAM17 for functions other than APP processing.

Estrogen causes astrocytes to increase their PPAR expression *in vitro* (Valles et al., [@B81]), probably via upregulation of PPAR mRNA. Estrogen also increases seladin-1 mRNA and seladin-1 protein expression *in vitro* (Benvenuti et al., [@B8]). This seladin-1 expression reduces the activation of caspase-3 by Aβ (Luciani et al., [@B50]). Specific agonists of ERα were much more effective in upregulating seladin-1 than specific agonists of ERβ, demonstrating that estrogen upregulates seladin-1 expression via ERα. Upregulation of seladin-1 probably occurs via classical mechanisms because the seladin-1 gene has an estrogen response element (ERE).

Bcl2 (B-cell lymphoma 2) protein family members can be either pro-apoptotic or anti-apoptotic and together regulate apoptosis via several mechanisms including release of Smac and activation of caspase-9 (Youle and Strasser, [@B93]). Certain pro-apoptotic Bcl2 family members, such as Bim, can block the anti-apoptotic activity of other Bcl2 family members (Wilson-Annan et al., [@B88]). Estrogen increases expression of the anti-apoptotic protein BclxL (Bclextra-long) *in vitro*, and this inhibits caspase-mediated proteolysis due to Aβ (Pike, [@B59]). The estrogen-induced increase in BclxL probably occurs via classical estrogen gene expression regulation because the BclxL gene has a putative ERE, and because the estrogen-induced inhibition of caspase-mediated proteolysis is prevented by ER blockers.

*In vivo*, Aβ activates JNK and also downregulates the anti-apoptotic Bclw and BclxL but upregulates the pro-apoptotic Bim on both the mRNA and protein levels (Yin et al., [@B91]; Yao et al., [@B89], [@B90]). Bclw and BclxL downregulation, and Bim upregulation, probably results from activation of cJun by JNK. Also, Bclw and BclxL downregulation, and Bim upregulation, are associated with release of Smac, which results in activation of caspase-9. RNA knockdown of Bclw did not lead to release of Smac in the absence of Aβ, while Bim knockdown substantially reduced but did not completely eliminate Smac release, suggesting that Aβ causes Smac release through some combination of different effects. Also *in vivo*, estrogen upregulates Bclw and downregulates Bim at both the mRNA and protein levels (Yao et al., [@B90]). Estrogen reduces Aβ-induced phosphorylation of JKN, which reduces but does not eliminate the effects of activated JNK on Bclw downregulation and Bim upregulation. It is still uncertain whether estrogen regulates Bclw and Bim via classical ER mechanisms or via signaling pathways. BclxL is probably regulated via classical ER mechanisms (see previous paragraph).

Estrogen increases superoxide dismutase (SOD1 or simply SOD) expression *in vitro* (Rao et al., [@B60]). The SOD so produced is effective in limiting damage due to OS. The estrogen-induced increase in SOD is believed to occur via ERα.

The mRNA for apoE fluctuates with cyclic changes in estrogen levels in parts of rat hippocampus and hypothalamus (Stone et al., [@B72]). Estrogen administration increases apoE mRNA and apoE protein in mouse and rat brain regions including cortex and hippocampus, but amounts of apoE mRNA upregulated by estrogen seem to depend on animal strain (Srivastava et al., [@B71]; Levin-Allerhand et al., [@B47]; Wang et al., [@B86]). Selective activation of ERα upregulated apoE while selective activation of ERβ downregulated apoE *in vitro* (Wang et al., [@B86]). It seems that ERα and ERβ exert antagonistic effects but that ERα overpowers ERβ since estrogen itself upregulates apoE. Administration of estrogen in ovariectomized mice significantly increased LRP in brain regions including hippocampus and cortex (Cheng et al., [@B13]). The increase in LRP seems to be independent of increases in apoE due to estrogen but the mechanism of LRP increase is unknown. Estrogen also upregulates Pgp expression (Abuznait et al., [@B1]).

Activation by estrogen either of ERα or ERβ upregulates expression of NEP mRNA and NEP protein *in vitro* (Liang et al., [@B49]). Activated ERα or ERβexert their influence mainly at EREs on the NEP gene. Activation of ERα or ERβ by selective drugs increases NEP expression less than estrogen itself, indicating that the effects of ERα and ERβ are roughly additive.

Computational representation and analysis {#s2}
-----------------------------------------

The interactions outlined in the previous two subsections are diagrammed in Figure [1](#F1){ref-type="fig"}, and are represented computationally in a computer program. The diagram is a directed graph, in which the graph elements are represented as nodes while their interactions are represented as links. Each node has a label representing a molecular species (e.g., Aβ) or condition (e.g., OS). Each node has a variable, numerical value associated with it, and that value is meant to correspond to an experimentally measureable quantity. However, due to the qualitative nature of the data on which the model is based, the correspondence between numerical variable values and experimental measurements is intended to be proportional rather than exact. To alleviate any ambiguity, node labels correspond to the actual variable names used in the computer program, emphasizing the fact that all reported numerical results directly pertain to computer model variables rather than experimental measurements. Node names reflect accepted nomenclature as closely as possible within the symbolic limitations of the programming language. Among other limitations, the programming language does not support Greek lettering, dashes, or spaces in element names, so accepted nomenclature was altered accordingly (e.g., Abeta, BACEmRNA, caspase3). To further distinguish model elements from the biological entities they represent, all element names are printed in monotype font (e.g., `Abeta`, `BACEmRNA`, `caspase3`).

![**Schematic diagram of the estrogen-Aβ model**. Model elements are represented using labels within geometric shapes (nodes). Each connection (link) leads from an origin element to a destination element whose level is influenced by that origin element. Arrowhead or tee endings represent positive or negative influence, respectively. Estrogen and cerebrovascular disease (CVD) are the main source elements, but any element with no connections leading to it is a source element. Alzheimer Disease (AD), with no connections leading from it, is the only sink element. The other element labels are defined in the text.](fphar-04-00016-g001){#F1}

Most nodes in the diagram are represented as ovals. Internal nodes both receive and send links, and all internal elements are represented as oval nodes. Source elements are those with no incoming links. The two main source elements, represented as inverted triangles, are `estrogen` and `CVD`, but many other source elements are represented as ovals. The single sink node, which sends no links, is `AD`, represented as an octagon. Links represent influence rather than binding. Thus, ERα activation increases seladin-1 mRNA expression by binding an ERE on the seladin-1 gene (see previous two subsections of Materials and Methods for references), but this binding is not represented in the model. Instead, the influence is represented by having `ERalpha` and `seladin1gene` each send a link to `seladin1mRNA`, since both `ERalpha` and `seladin1gene` influence `seladin1mRNA` expression.

Links are either positive (arrowhead ending) or negative (tee ending). Due to the qualitative nature of the data, all links have absolute value one unless information is available to specify a different value. This occurs in two places in the model. First, one molecule of LRP binds one molecule of APP so LRP APP binding helps produce one molecule of Aβ, but one molecule of apoE can bind multiple molecules of Aβ and so clear multiple Aβ molecules after the LRP-apoE complex is internalized. Thus, the link from `LRPAPP` to `Abeta` has value +1 but, parsimoniously, the link from `LRPapoE` to `Abeta` has value −2. Second, activation of ERα and ERβ respectively increase and decrease apoE mRNA expression, but estrogen, which activates both ERs, produces a net increase in apoE mRNA expression. Thus, the link from `ERalpha` to `apoEmRNA` has value +2 while the link from `ERbeta` to `apoEmRNA` has value −1.

The interactions depicted in the diagram are all represented in a computer program written in a specialized meta-language known as Maude (Clavel et al., [@B16]). Maude is a declarative programming language in which statements are declarations of facts rather than imperative commands, and for that reason Maude programs are also referred to as specifications. The main difference between the two computational approaches is that in an imperative program, commands execute in a specified order while in a specification, declarations execute in an unspecified order provided they are applicable. Both imperative and declarative programming languages can be used to create computer models of real systems but, because the statements in a specification are declarations of facts, a declarative specification can be used not only to simulate a system but also to analyze it using the methods of temporal-logic (Huth and Ryan, [@B38]). Both simulation and temporal-logic analysis will be applied here in evaluating the model of the contribution of estrogen to Aβ regulation (called the estrogen-Aβ model).

A specification in Maude is based on an underlying algebra characterized by a set of data types and allowed operations on, and between, those data types (Clavel et al., [@B16]). Each element in the estrogen-Aβ model is represented by an operator that assigns an integer value to that element. For example, the operator `estrogen(1)` assigns the integer value 1 to `estrogen` and makes that assignment a `State` of the system. A concatenation operator allows multiple `State` expressions to be combined into a single `State` expression. Some other operators serve only as integer constants that are used as thresholds or levels of constitutive expression. Specifically, the operators `thrCY`, `thrERK`, `thrOS`, and `thrAD` are the input thresholds for activation of `cytokine`, `ERK`, `OS`, and `AD` and they take integer values of 6, 6, 9, and 12, respectively. The operators `conBACEmRNA`, `conBACE`, and `conAbeta` assign integer baselines (i.e., constitutive expression levels) of 6 to each of `BACEmRNA`, `BACE`, and `Abeta`. These thresholds and levels of constitutive expression, combined with the interaction (i.e., link) values described above, constitute the full set of parameters of the model. Using these parameters, the interactions diagrammed in Figure [1](#F1){ref-type="fig"}, and the interaction descriptions provided in the previous two subsections of Materials and Methods, the modeling results presented in Results should be reproducible.

Declarations in Maude are either equations or rules, and together they describe the system being modeled. Both equations and rules are based on the underlying algebra and its data types and allowed operations. The main difference between them is that applicable equations must execute, but applicable rules may execute or not. This difference is critical for the ability of Maude to analyze a system because she can follow not just one but every possible order of applicable rule executions and thereby explore the entire model state space. On each path through the state space, Maude executes an applicable rule and then executes every equation made applicable by execution of that rule. She then executes another applicable rule, but the order of rule executions is different for each path. By constructing and then searching all possible paths through the state space, Maude can evaluate temporal-logic propositions such as whether one specific state always leads to another specific state, or whether one specific state pertains only until another specific state occurs, and so on (Huth and Ryan, [@B38]; Clavel et al., [@B16]).

The integer values assigned by the operators to model elements are kept non-negative. For many elements, this is accomplished by treating their integer levels simply as binary (i.e., their levels are of the integer data type but they are restricted to values of 0 or 1). Other elements are allowed to take multiple integer levels but they are kept non-negative through logic and/or by providing one of the baseline, constitutive levels of expression so that negative inputs do not force their levels to go below zero. Source nodes, which receive no inputs, have their levels set at the beginning of a simulation or analysis. Through the many forward and recurrent (i.e., feedback) links in the model, whose effects are described by rules and equations, the levels of the source and internal nodes affect the levels of the other internal nodes and, ultimately, the sink node.

The Maude specification for the estrogen-Aβ model is called `ALZHEIMERE`, where the last `E` stands for estrogen. Each declaration in `ALZHEIMERE` describes how the level of one element is affected by the levels of its input elements. Only three declarations in the model are rules. These are the declarations that describe the activation of `ERalpha`, `ERbeta`, and `PKCalpha` by `estrogen`. For example, Maude code for the declaration that determines the activation of `ERalpha` is shown below (all Maude code is written in `monotype` font).

    crl [ERalphaAct]:estrogen(X1) ERalphaAg(X2)
             ERalpha(Y) =>
             estrogen(X1) ERalphaAg(X2)
             ERalpha(if X1 > 0 or
              X2 > 0 then 1 else 0 fi)
             if Y =/= if X1 > 0 or
              X2 > 0 then 1 else 0 fi.

In this rule, called `ERalphaAct`, the levels of `estrogen`, the ERα agonist `ERalphaAg`, and `ERalpha` are represented by integer variables `X1`, `X2`, and `Y`, respectively. The rule specifies that the levels of `estrogen` and `ERalphaAg` remain the same but the level of `ERalpha` goes to 1 if either `X1` or `X2` is greater than 0, or goes to 0 if neither `X1` nor `X2` is greater than 0. Note that the rule is conditional (`crl`), so that the level of `ERalpha` can *change* to 1 or 0 but will not be reassigned 1 or 0 if it had that value already. The conditionality of the rule makes it applicable only if executing it will change the value assigned to `ERalpha`. Note also that the conditional rule limits the value of `ERalpha` to binary values. The conditional rules that determine the activation of `ERbeta` and `PKCalpha` (not shown) are similar.

All of the other declarations in `ALZHEIMERE` are equations and, more specifically, conditional equations. For example, the conditional equation (`ceq`) that determines the level of `BACEmRNA` expression, called `BACEmessage`, is shown below.

    ceq [BACEmessage]:BACEgene(G) BACEASRNA(X1)
             HIF(X2) PPAR(Y)
             BACEmRNA(Z) =
             BACEgene(G) BACEASRNA(X1)
             HIF(X2) PPAR(Y)
             BACEmRNA(((conBACEmRNA
              + X1 + X2) - Y) * G)
             if Z =/= ((conBACEmRNA
              + X1 + X2) - Y) * G.

In this equation the levels of `BACEgene`, `BACEASRNA`, `HIF`, `PPAR`, and `BACEmRNA` are represented by the integer variables `G`, `X1`, `X2`, `Y`, and `Z`, respectively. The equation specifies that the levels of `BACEgene`, `BACEASRNA`, `HIF`, and `PPAR` remain unchanged but the level of `BACEmRNA` equals the sum of its positive inputs `X1` and `X2` and its constitutive level `conBACEmRNA`, minus its negative input `Y`, and this difference is multiplied by `G`, which is 1 if the gene is present but 0 if it is absent. The conditionality of the equation makes it applicable only if executing it will change the value assigned to `BACEmRNA`.

The rules and equations need to be conditional to prevent them from executing if doing so would not change the value of any element. Without such a condition, the declaration that determines the level of any element, whether equation or rule, would continue executing ad infinitum, simply replacing the value assigned by its operator with the identical value. With such conditions, declarations do not execute unless doing so would change the value of an element, and the specification terminates when no further changes to element values can be made. The Maude specification `ALZHEIMERE` terminates for all start configurations (i.e., assignments of source node values) that are reported in Results.

In the context of declarative programming, temporal-logic analysis is also known as model checking. Model checking for Maude specification `ALZHEIMERE` is carried out using a separate specification called `MC-ALZHEIMERE`. The main function of `MC-ALZHEIMERE` is to define a set of properties of interest that can be verified through executions of rules and equations in `ALZHEIMERE`. For example, the following (non-conditional) equation indicates when the property `NEPeq3` is true.

    eq AM(S NEP(3)) |= NEPeq3 = true.

(where `|` = is the logical connector "satisfies"). The operator `AM` is a "wrapper" and the term `AM(S NEP(3))` simply defines the state of the system when `NEP` is at level 3 and all other elements, at whatever levels, are subsumed under the variable `S`. The equation specifies that the system with `NEP` at level 3 satisfies the proposition that `NEPeq3` is true, regardless of other element levels. In executing this equation in `MC-ALZHEIMERE`, Maude will determine, given some initial configuration of the model (i.e., assignments of source node values) and rule and equation executions in `ALZHEIMERE`, that `NEPeq3` is true, or it will be unable to execute further rules and equations in `ALZHEIMERE` and will "deadlock" without determining that `NEPeq3` is true. Temporal-logic analysis involves verification of properties individually or combined into more complex logical statements. Both simulation and temporal-logic analysis will be used to generate results on, and to derive predictions from, the estrogen-Aβ model.

Results
=======

The Maude specification `ALZHEIMERE` computationally describes the interactions depicted in Figure [1](#F1){ref-type="fig"}, which represent many of the recently identified contributions that estrogen makes to the regulation of Aβ. By representing these interactions the Maude model can indicate what they mean in the aggregate. More specifically, the model can indicate what effects different combinations of hormone or estrogen receptor agonists and other drugs might have on the level of Aβ, whether under conditions of low estrogen alone or exacerbated by mild CVD. The Maude model, like any model, is a hypothesis that needs to be verified experimentally, and many of the results of model simulation and analysis reported in this section can be taken as predictions of the model (see [Discussion](#s1){ref-type="sec"}).

Simulations begin by finding the normal, baseline level of Aβ in the model. This is done by setting all of the source elements to their normative levels (including the normative level of estrogen) and then letting Maude execute all applicable equations and rules until a terminal state is reached. In Maude, a rule execution is known as a "rewrite" while an equation execution is known as a "reduction." Since rule executions (i.e., rewrites) can make equations applicable and so lead to equation executions (i.e., reductions), both rule and equation executions can be produced using rewrite commands. A command to produce twenty rewrites in the Maude specification `ALZHEIMERE` from the normative start-state is shown below.

    rewrite [20] in ALZHEIMERE : PPARgene(1)
    PS1gene(1) PEN2gene(1) NICgene(1)
    seladin1gene(1) GGA3gene(1) APPgene(1)
    LRPgene(1) apoEgene(1) Pgpgene(1)
    BACEASgene(1) BACEmigene(1) BACEgene(1)
    NEPgene(1) BclxLgene(1) Bclwgene(1)
    Bimgene(1) estrogen(1) SNX6(1) RAGE(1)
    hepSul(1) RTN3(1) RAP(1) IDE(1) ACE(1)
    CVD(0) NSAID(0) HIFblock(0) caspBlock(0)
    ERKblock(0) PERKblock(0) ERalphaAg(0)
    ERbetaAg(0) hypoxia(0) HIF(0) ischemia(0)
    PERK(0) eIF2(0) cytokine(0) PPARmRNA(0)
    PPAR(0) OS(0) JNK(0) cJun(0) SOD(0) ERK(0)
    PS1mRNA(0) PS1(0) PEN2mRNA(0) PEN2(0)
    nicastrin(0) gammaSec(0) PKCalpha(0)
    alphaSec(0) Smac(0) XIAP(0) caspase9(0)
    caspase3(0) seladin1mRNA(0) seladin1(0)
    GGA3(0) APP(0) Abeta(0) AD(0) LRPmRNA(0)
    LRP(0) apoEmRNA(0) apoE(0) LRPapoE(0)
    LRPAPP(0) BECLRP(0) PgpmRNA(0) Pgp(0)
    BACEASRNA(0) BACEmiRNA(0) BACEmRNA(0)
    BACE(0) NEPmRNA(0) NEP(0) BclxLmRNA(0)
    BclxL(0) BclwmRNA(0) Bclw(0) BimmRNA(0)
    Bim(0) ERalpha(0) ERbeta(0)

The order of operators in this list is arbitrary and is, in any case, determined internally by Maude. In the normative start-state, all genes (e.g., `APPgene`) and all endogenous factors (e.g., `SNX6`) are present, but all agonists (e.g., `ERalphaAg`) and other drugs (e.g., `NSAID`) are absent. Also in the normative state `estrogen` is present but `CVD` is absent. Note that a source element is present or absent when its level is 1 or 0, respectively. In the start-state the levels of all of the internal nodes, including `Abeta`, and the sink node `AD`, are set to 0. Twenty rewrites is more than enough to ensure that all applicable rules will execute. The result of rewriting from the normative start-state in Maude specification `ALZHEIMERE` is shown below.

    result State: CVD(0) hypoxia(0) HIF(0)
    HIFblock(0) ischemia(0) PERK(0) PERKblock(0)
    eIF2(0) cytokine(0) PPARgene(1) PPARmRNA(2)
    PPAR(2) NSAID(0) OS(0) JNK(0) cJun(0) SOD(1)
    ERK(0) ERKblock(0) PS1gene(1) PS1mRNA(1)
    PS1(1) PEN2gene(1) PEN2mRNA(1) PEN2(1)
    NICgene(1) nicastrin(2) gammaSec(1)
    PKCalpha(1) alphaSec(1) Smac(0) XIAP(0)
    caspase9(0) caspase3(0) caspBlock(0)
    seladin1gene(1) seladin1mRNA(1) seladin1(1)
    GGA3gene(1) GGA3(2) SNX6(1) APPgene(1)
    APP(1) Abeta(2) AD(0) LRPgene(1) LRPmRNA(2)
    LRP(2) apoEgene(1) apoEmRNA(2) apoE(2)
    LRPapoE(2) LRPAPP(1) BECLRP(2) Pgpgene(1)
    PgpmRNA(2) Pgp(2) RAGE(1) BACEASgene(1)
    BACEASRNA(2) BACEmigene(1) BACEmiRNA(1)
    BACEgene(1) BACEmRNA(6) BACE(8) hepSul(1)
    RTN3(1) RAP(1) IDE(1) ACE(1) NEPgene(1)
    NEPmRNA(3) NEP(3) BclxLgene(1) BclxLmRNA(2)
    BclxL(2) Bclwgene(1) BclwmRNA(1) Bclw(1)
    Bimgene(1) BimmRNA(1) Bim(1) estrogen(1)
    ERalpha(1) ERbeta(1) ERalphaAg(0)
    ERbetaAg(0)

Again the order of operators in the list is arbitrary. The levels of the source elements remain unchanged while the levels of many, but not all, of the internal elements have changed. Note, for example, that with `CVD` absent, neither `hypoxia` nor `ischemia` occurs. Consequently, neither `HIF` nor `PERK` is activated. With `estrogen` present, both `ERalpha` and `ERbeta` are activated. Also, with `CVD` absent and `estrogen` present, `OS` does not occur and `cytokine`, `JNK`, `ERK`, and `caspase3` are not activated. In this, the normative baseline state, the heavily regulated `BACEmRNA`, `BACE`, and `Abeta` take integer values of 6, 8, and 2, respectively, and `AD` does not occur. These normative results are shown in Row 1 of Table [1](#T1){ref-type="table"}. It is imperative to reiterate (see [Computational Representation and Analysis](#s2){ref-type="sec"}) that the levels of the various model elements are meant to be proportional to levels of real molecules, and that changes in model element levels due to changes in model inputs constitute the relevant modeling results.

###### 

**Simulating the effects of estrogen and its lack, and of selective ERα and ERβ agonists, on BACEmRNA, BACE, and Aβ levels in the absence of CVD in the model**.

  Number   Estrogen   ERalphaAg   ERbetaAg   CVD   NSAID   HIFblock   caspBlock   ERalpha   ERbeta   OS   caspase3   BACEmRNA   BACE   Abeta   AD
  -------- ---------- ----------- ---------- ----- ------- ---------- ----------- --------- -------- ---- ---------- ---------- ------ ------- ----
  1        1          0           0          0     0       0          0           1         1        0    0          6          8      2       0
  2        0          0           0          0     0       0          0           0         0        1    1          8          11     11      0
  3        0          0           0          0     1       0          0           0         0        1    1          7          10     10      0
  4        0          0           0          0     0       1          0           0         0        1    1          8          11     11      0
  5        0          0           0          0     0       0          1           0         0        1    0          8          10     10      0
  6        0          0           0          0     1       0          1           0         0        1    0          7          9      9       0
  7        0          0           0          0     1       1          1           0         0        1    0          7          9      9       0
  8        0          0           1          0     0       0          0           0         1        1    1          7          10     11      0
  9        0          0           1          0     1       0          0           0         1        1    1          6          9      10      0
  10       0          0           1          0     0       1          0           0         1        1    1          7          10     11      0
  11       0          0           1          0     0       0          1           0         1        1    0          7          9      10      0
  12       0          0           1          0     1       0          1           0         1        1    0          6          8      9       0
  13       0          0           1          0     1       1          1           0         1        1    0          6          8      9       0
  14       0          1           0          0     0       0          0           1         0        0    0          6          8      4       0
  15       0          1           0          0     1       0          0           1         0        0    0          5          7      3       0
  16       0          1           0          0     0       1          0           1         0        0    0          6          8      4       0
  17       0          1           0          0     0       0          1           1         0        0    0          6          8      4       0
  18       0          1           0          0     1       1          1           1         0        0    0          5          7      3       0

*Each row shows the consequences of a specific start configuration (the seven source elements heading the columns on the left) for a selected set of elements of interest (the eight elements heading the columns on the right). The row numbers appear in the leftmost column*.

Lowering Aβ in the absence of estrogen and the absence of CVD
-------------------------------------------------------------

Table [1](#T1){ref-type="table"} tabulates the results of model simulations (i.e., rewrites in `ALZHEIMERE`) initiated from many different start configurations but all in the absence of `CVD`. Whereas Row 1 of Table [1](#T1){ref-type="table"} shows the normal, baseline state of the model, Row 2 shows the consequences for the model of removing `estrogen`. Neither `ERalpha` nor `ERbeta` are activated in the absence of `estrogen` and in the absence of any estrogen receptor agonists. This lack leads to the activation of `OS` and `caspase3`. That and other changes in internal element levels lead to increases of `BACEmRNA` from 6 to 8, of `BACE` from 8 to 11, and of `Abeta` from a normative level of 2 to 11. Because the model is focused on Aβ regulation, and because the actual relationship between Aβ and AD is still incompletely understood, the Aβ threshold at which AD occurs is set arbitrarily in the model. This threshold is set at the relatively high level of 12, and `AD` occurs only if `Abeta` is strictly greater than 12, so `AD` does not occur in the absence of both `estrogen` and `CVD` (Row 2 of Table [1](#T1){ref-type="table"}). The more important finding in this case is the change in `Abeta`, and the increase in `Abeta` from 2 to 11 is substantial in the context of the model.

Considering the many ways in which `estrogen` limits `Abeta` production in the model, this drastic rise in `Abeta` level in the absence of `estrogen` is not surprising, even without `CVD`. Through the `ERalpha` and `ERbeta` receptors, `estrogen` reduces `BACEmRNA` expression by increasing `PPAR` expression (via upregulation of `PPARmRNA`), and the decrease in `BACEmRNA` leads to a decrease in `BACE` and so in `Abeta`. Also through its classical receptors, `estrogen` decreases `Abeta` by increasing expression of `LRP`, `apoE`, `NEP`, and `Pgp`. Less directly, `estrogen` reduces `Abeta` because it reduces `OS` by upregulating `SOD`, and suppresses `caspase3` activation by upregulating `seladin1` and `BclxL`. Because `OS` and `caspase3` activation can augment `BACE` levels, estrogen reduces `BACE` and so reduces `Abeta` by reducing `OS` and `caspase3` activation. Through its activation of `PKCalpha`, `estrogen` further reduces `Abeta` by activating `alphaSec`, which diverts `APP` away from the amyloidogenic pathway. Due to the presence of numerous positive feedback loops by which `Abeta` upregulates `BACE` and so drives its own accumulation, `estrogen` can, essentially, reduce `Abeta` by reducing this positive feedback drive. Thus, `estrogen` exerts downward pressure on `Abeta` in about 10 different ways in the model, and so the dramatic upraising of `Abeta` in the absence of `estrogen` is not surprising.

The rest of Table [1](#T1){ref-type="table"} is concerned with the question of how various drugs, alone or in combination, could help keep `Abeta` levels down in the absence of `estrogen` (the state of 0 `estrogen` in the model corresponds to a worst-case post-menopausal scenario). In the model the effect of `NSAID` is to augment the expression of `PPARmRNA` and so of `PPAR` itself (other possible effects of NSAIDs are not represented for simplicity). Because `PPAR` suppresses `BACEmRNA` expression, `NSAID` reduces `BACEmRNA` and, consequently, also reduces `BACE` and `Abeta`. With links of absolute value 1 for the interactions that mediate these `NSAID` effects, activation of `NSAID` (i.e., changing `NSAID` level from 0 to 1) results in a decrease of 1 for each of `BACEmRNA`, `BACE`, and `Abeta` (compare Rows 3 and 2 of Table [1](#T1){ref-type="table"}).

The function of `HIFblock` in the model is to keep `HIF` at level 0 even in the presence of `hypoxia`. In the model, `hypoxia` is brought about by `CVD` and `hypoxia` does not occur without it. For the simulations whose results are listed in Table [1](#T1){ref-type="table"}, `CVD` is absent, `hypoxia` does not occur, and `HIF` is not activated, so blocking `HIF` using `HIFblock` should have no effect. Indeed it does not (compare Rows 4 and 2 of Table [1](#T1){ref-type="table"}). The presence of `HIFblock` does not reduce `Abeta` from its high level of 11 in the absence of `estrogen`.

The function of `caspBlock` in the model is, likewise, to keep `caspase3` at level 0 despite activation of the pro-apoptotic pathway. This pathway is activated by `OS` in the model and is regulated by many factors, some of which are under the control of `estrogen` (e.g., `BclxL` and `seladin1`). The occurrence of `OS` in the model is determined by the level of `Abeta` and by the activation of `cytokine`, which itself depends on the level of `Abeta`, and the rise in `Abeta` resulting from the absence of `estrogen` is enough to cause `OS` and so activate `caspase3`. In this case blocking `caspase3` using `caspBlock` should have a beneficial effect. Indeed it does (compare Rows 5 and 2 of Table [1](#T1){ref-type="table"}). Note that `caspase3` exerts its effects on `BACE` rather than on `BACEmRNA`, so the presence of `caspBlock` does not change the level of `BACEmRNA` but it decreases the levels both of `BACE` and of `Abeta` by 1.

Two factors that independently produce the same effect could produce a greater effect in combination, especially if they work via different pathways. This is the case for `NSAID` and `caspBlock` (compare Rows 6 and 2 of Table [1](#T1){ref-type="table"}). Applying `NSAID` and `caspBlock` together reduces `BACEmRNA` from 8 to 7, `BACE` from 11 to 9, and `Abeta` from 11 to 9. Since `HIF` is activated only by `CVD` and `CVD` is not present in this set of simulations, `HIFblock`, even in combination with other factors, should provide no benefit. As expected, in the absence of both `estrogen` and `CVD`, `HIFblock` in combination with `NSAID` and `caspBlock` is not more effective in reducing `Abeta` than are `NSAID` and `caspBlock` without `HIFblock` (compare Rows 7 and 6 of Table [1](#T1){ref-type="table"}). These simulations suggest than in a state of very low estrogen, the rise in Aβ could be slightly offset using an NSAID-class drug that promotes PPAR expression or a compound that blocks caspase-3 activation, and that their combination would be more effective than either one alone. This set of simulations further suggests that, in the absence of CVD, compounds that block HIF activation would not be effective in lowering Aβ levels consequent to estrogen depletion, even in combination with other compounds that work via different pathways.

An alternative to estrogen therapy is to administer drugs that act as agonists for specific estrogen receptors. This alternative is explored computationally using the model, and the results are tabulated in the second and third blocks of Table [1](#T1){ref-type="table"}. Again, both `estrogen` and `CVD` are absent. The simulations show that the administration of an agonist of ERβ (`ERbetaAg`) provides no benefit in the model. The effect of `ERbetaAg` alone is to decrease `BACEmRNA` from 8 to 7 and to decrease `BACE` from 11 to 10, but `ERbetaAg` alone does not decrease `Abeta` (compare Rows 8 and 2 of Table [1](#T1){ref-type="table"}). This initial result exposes the main drawback of `ERbetaAg`. Although it provides some of the same benefits as `estrogen`, `ERbetaAg` causes a decrease in `apoE`. Specifically, `apoE` is expressed at level 1 without `estrogen` but at level 0 with the addition of `ERbetaAg`. Because `ERbetaAg` suppresses `apoE` it cannot lower `Abeta` despite lowering `BACEmRNA` and `BACE`. In the model, `ERbetaAg` provides no benefit by itself.

As was the case previously without `estrogen` and without `CVD`, `NSAID` and `caspBlock` both reduce `Abeta` in the presence of `ERbetaAg` but `HIFblock` does not. Again as in the previous case, `NSAID` and `caspBlock` work better together than separately but `HIFblock` remains ineffective even in combination with `NSAID` and `caspBlock` (see Rows 9 through 13 in Table [1](#T1){ref-type="table"}). Because it reduces the level of `apoE`, `ERbetaAg` provides no benefit over `NSAID` and `caspBlock` despite lowering both `BACEmRNA` and `BACE`. The model suggests that ERβ agonists would not be effective replacements for estrogen for the purpose of Aβ reduction.

The situation is dramatically different with administration of an ERα agonist (`ERalphaAg`). The presence of `ERalphaAg` alone reduces `BACEmRNA` from 8 to 6, `BACE` from 11 to 8, and `Abeta` from 11 to 4 (compare Rows 14 and 2 of Table [1](#T1){ref-type="table"}). There are three reasons why `ERalphaAg` alone reduces `Abeta` substantially while `ERbetaAg` alone does not reduce `Abeta` at all. First, `ERalphaAg` increases `apoE` while `ERbetaAg` decreases it. Specifically, `apoE` is expressed at level 1 without `estrogen`, is expressed at level 0 with the addition of `ERbetaAg` alone, but is expressed at level 3 with the addition of `ERalphaAg` alone. Second, `ERalphaAg` increases `seladin1`, but `ERbetaAg` has no effect on it. Third, the combined effects of `ERalphaAg`, including increases in `apoE`, `seladin1`, `NEP`, and `Pgp`, are enough to bring `Abeta` below the threshold at which it activates `cytokine` and `OS`. By preventing `OS` in the absence of `estrogen`, `ERalphaAg` breaks the main, pathological positive feedback loop by which `Abeta` drives its own accumulation, and that keeps `Abeta` levels down.

As before in the absence of `estrogen`, or with `ERbetaAg`, `NSAID` is also able to reduce each of `BACEmRNA`, `BACE`, and `Abeta` by 1 in combination with `ERalphaAg` (compare Rows 15 and 14 of Table [1](#T1){ref-type="table"}). Again as before in the absence of `CVD`, `HIFblock` is ineffective in reducing `Abeta` (or `BACEmRNA` or `BACE`) with `ERalphaAg` because `HIF` is not activated unless `CVD` is present to cause `hypoxia` (compare Rows 16 and 14 of Table [1](#T1){ref-type="table"}). Because `ERalphaAg`, like `estrogen` itself, increases `seladin1`, and because `seladin1` suppresses `caspase3`, `caspBlock` is also ineffective in reducing `Abeta` (or `BACEmRNA` or `BACE`) with `ERalphaAg` (compare Rows 17 and 14 of Table [1](#T1){ref-type="table"}). Thus, in the absence of `estrogen` and `CVD`, a combination of `ERalphaAg` and `NSAID` is capable of bringing `Abeta` back down to 3, which is close to the normative level of 2 (compare Rows 18 and 1 of Table [1](#T1){ref-type="table"}). The model suggests that, in the post-menopausal state of low estrogen, the level of Aβ could be reduced almost as effectively with a combination of an ERα agonist and an NSAID as with estrogen itself.

Lowering Aβ in the presence of CVD
----------------------------------

Lack of `estrogen` leads to a pronounced upraising of `Abeta` in the model, as described in the previous subsection and as shown in Rows 1 and 2 of Table [1](#T1){ref-type="table"}. This is exacerbated by `CVD`, as shown in Row 1 of Table [2](#T2){ref-type="table"}. In the absence of `estrogen` but in the presence of `CVD`, `BACEmRNA` rises from a normative level of 6 to 9, `BACE` from a normative 8 to 13, and `Abeta` from a normative 2 to 13 (compare Row 1 of Table [1](#T1){ref-type="table"} with Row 1 of Table [2](#T2){ref-type="table"}). With the `AD` threshold set arbitrarily at 12 in the model, the absence of `estrogen` combined with the presence of `CVD` raises `Abeta` enough to cause `AD`. The obvious implication here is that CVD would be expected to exacerbate the Aβ accumulation due to low estrogen, especially since CVD raises Aβ via pathways different from those by which estrogen lowers it (see Figure [1](#F1){ref-type="fig"}).

###### 

**Simulating the effects of estrogen and its lack, and of selective ERα and ERβ agonists, on BACE mRNA, BACE, and Aβ levels in the presence of CVD in the model**.

  Number   Estrogen   ERalphaAg   ERbetaAg   CVD   NSAID   HIFblock   caspBlock   ERalpha   ERbeta   OS   caspase3   BACEmRNA   BACE   Abeta   AD
  -------- ---------- ----------- ---------- ----- ------- ---------- ----------- --------- -------- ---- ---------- ---------- ------ ------- ----
  1        0          0           0          1     0       0          0           0         0        1    1          9          13     13      1
  2        0          0           0          1     1       0          0           0         0        1    1          8          12     12      0
  3        0          0           0          1     0       1          0           0         0        1    1          8          12     12      0
  4        0          0           0          1     0       0          1           0         0        1    0          9          12     12      0
  5        0          0           0          1     1       1          0           0         0        1    1          7          11     11      0
  6        0          0           0          1     1       0          1           0         0        1    0          8          11     11      0
  7        0          0           0          1     0       1          1           0         0        1    0          8          11     11      0
  8        0          0           0          1     1       1          1           0         0        1    0          7          10     10      0
  9        0          0           1          1     0       0          0           0         1        1    1          8          12     13      1
  10       0          0           1          1     1       0          0           0         1        1    1          7          11     12      0
  11       0          0           1          1     0       1          0           0         1        1    1          7          11     12      0
  12       0          0           1          1     0       0          1           0         1        1    0          8          11     12      0
  13       0          0           1          1     1       1          0           0         1        1    1          6          10     11      0
  14       0          0           1          1     1       0          1           0         1        1    0          7          10     11      0
  15       0          0           1          1     0       1          1           0         1        1    0          7          10     11      0
  16       0          0           1          1     1       1          1           0         1        1    0          6          9      10      0
  17       0          1           0          1     0       0          0           1         0        0    0          8          11     7       0
  18       0          1           0          1     1       0          0           1         0        0    0          6          9      5       0
  19       0          1           0          1     0       1          0           1         0        0    0          6          9      5       0
  20       0          1           0          1     0       0          1           1         0        0    0          8          11     7       0
  21       0          1           0          1     1       1          0           1         0        0    0          5          8      4       0
  22       0          1           0          1     1       1          1           1         0        0    0          5          8      4       0
  23       1          0           0          1     0       0          0           1         1        0    0          7          10     4       0
  24       1          0           0          1     1       0          0           1         1        0    0          6          9      3       0
  25       1          0           0          1     0       1          0           1         1        0    0          6          9      3       0
  26       1          0           0          1     0       0          1           1         1        0    0          7          10     4       0
  27       1          0           0          1     1       1          0           1         1        0    0          5          8      2       0
  28       1          0           0          1     1       1          1           1         1        0    0          5          8      2       0

*Each row shows the consequences of a specific start configuration (the seven source elements heading the columns on the left) for a selected set of elements of interest (the eight elements heading the columns on the right). The row numbers appear in the leftmost column*.

As before, in the absence of both `estrogen` and `CVD` (Rows 3 and 5 of Table [1](#T1){ref-type="table"}), `NSAID` and `caspBlock` are also effective in lowering `Abeta` in the absence of `estrogen` but in the presence of `CVD` (Rows 2 and 4 of Table [2](#T2){ref-type="table"}). Furthermore, because `CVD`, and the `hypoxia` it causes are present, `HIFblock` is effective in lowering `Abeta` in this case (Row 3 of Table [2](#T2){ref-type="table"}) whereas it was not in the case of no `CVD` (Row 4 of Table [1](#T1){ref-type="table"}). Also with `estrogen` absent but `CVD` present, `NSAID`, `HIFblock`, and `caspBlock` are more effective in combination than separately (Rows 5 through 8 of Table [2](#T2){ref-type="table"}). Specifically, in the absence of `estrogen` but in the presence of `CVD`, each of `NSAID`, `HIFblock`, and `caspBlock` can lower `BACE` and `Abeta` by 1 and their effects are additive. Although each of `NSAID` and `HIFblock` can lower `BACEmRNA` by 1, `caspBlock` has no effect on `BACEmRNA`. The lack of effect of `caspBlock` on `BACEmRNA` results because `caspase3` bypasses `BACEmRNA` and works directly to increase `BACE` by suppressing `GGA3`. These simulations suggest than in a state of very low estrogen combined with incipient CVD, the rise in Aβ could be slightly offset using an NSAID-class drug that promotes PPAR expression, or a compound that blocks HIF, or a compound that blocks caspase-3 activation, and that administration of any two, or all three, of the compounds in combination would be more effective than any one of the three administered alone.

Although the level of `Abeta` is a bit higher with `estrogen` absent but `CVD` present, the effects of `ERbetaAg` in this case (Rows 9 through 16 of Table [2](#T2){ref-type="table"}) are similar to those with `estrogen` and `CVD` both absent (Rows 8 through 13 of Table [1](#T1){ref-type="table"}) in the sense that `ERbetaAg` can lower `BACEmRNA` by 1, and thereby lower `BACE` by 1, but it has no net effect on `Abeta`. As with `estrogen` absent but `CVD` present (Rows 1 through 8 of Table [2](#T2){ref-type="table"}), each of `NSAID`, `HIFblock`, and `caspBlock` can lower `BACE` and `Abeta` by 1 and their effects are additive, and `NSAID` and `HIFblock` lower `BACE` by lowering `BACEmRNA` while `caspBlock` lowers `BACE` without also lowering `BACEmRNA` (Rows 9 through 16 of Table [2](#T2){ref-type="table"}). Because `ERbetaAg`, like `estrogen` itself, reduces `BACEmRNA` via `PPAR`, both `BACEmRNA` and `BACE` are lower, under all combinations of `NSAID`, `HIFblock`, and `caspBlock`, in the presence of `ERbetaAg` when `estrogen` is absent but `CVD` is present (compare Rows 9 through 16 with Rows 1 through 8 of Table [2](#T2){ref-type="table"}). However, because `ERbetaAg` administered in the absence of `estrogen` reduces `apoE` from 1 to 0, the net effect of `ERbetaAg` on `Abeta` is 0. The implication of these modeling results is that, under conditions of low estrogen and incipient CVD, administration of an ERβ agonist would provide no benefit in terms of lowering Aβ.

In sharp contrast to the overall lack of benefit of `ERbetaAg`, administration of `ERalphaAg` provides a substantial benefit in terms of lowering `Abeta` with `estrogen` absent but `CVD` present (Rows 17 through 22 of Table [2](#T2){ref-type="table"}), as it had previously with `estrogen` and `CVD` both absent (Rows 14 through 18 of Table [1](#T1){ref-type="table"}). Addition of `ERalphaAg` alone reduces `BACEmRNA` from 9 to 8, `BACE` from 13 to 11, and `Abeta` from 13 to 7 (compare Rows 17 and 1 of Table [2](#T2){ref-type="table"}). The sharp drop in `Abeta` occurs because the suppression of `Abeta` production, and the promotion of `Abeta` elimination, due to `ERalphaAg` are enough to prevent `Abeta` from rising about the threshold for activation of `OS`, and this breaks the main, pathological positive feedback loop by which `Abeta` drives its own accumulation in the model. `OS` is among the factors that activate `caspase3`, while `seladin1` is among the factors that inactivate it, so by preventing `OS` and promoting `seladin1`, `ERalphaAg` is able to suppress `caspase3`. For this reason, `caspBlock` does not provide additional benefit in terms of lowering `Abeta` when `ERalphaAg` is added under conditions in which `estrogen` is absent but `CVD` is present (compare Rows 20 and 17 of Table [2](#T2){ref-type="table"}).

Although `caspBlock` is ineffective in combination with `ERalphaAg` under conditions in which `estrogen` is absent but `CVD` is present, each of `NSAID` or `HIFblock` is even more effective in combination with `ERalphaAg` than either is alone (compare Rows 17 through 19 with Rows 1 through 3 in Table [2](#T2){ref-type="table"}). Specifically, with `estrogen` absent but `CVD` present, `NSAID` or `HIFblock` alone reduces `Abeta` from 13 to 12 (Rows 1 through 3 of Table [2](#T2){ref-type="table"}), but in combination with `ERalphaAg`, `NSAID`, or `HIFblock` reduces `Abeta` from 7 to 5 (Rows 17 through 19 of Table [2](#T2){ref-type="table"}). Thus, with `estrogen` absent but `CVD` present, `NSAID` or `HIFblock` alone reduces `Abeta` by 1, but either reduces `Abeta` by 2 in combination with `ERalphaAg` (compare Rows 17 through 19 with Rows 1 through 3 in Table [2](#T2){ref-type="table"}). The reason for the larger drop is that `NSAID` or `HIFblock` in combination with `ERalphaAg` lowers `Abeta` enough to prevent the activation of `cytokine`, which indirectly increases `BACE` and so increases `Abeta`. This synergistic (more than additive) effect of `ERalphaAg` combined with either `NSAID` or `HIFblock` is due to a threshold effect, specifically a failure to cross the `cytokine` threshold. Similarly, the dramatic effect of `ERalphaAg` alone, which reduces `Abeta` from 11 to 4 with `estrogen` and `CVD` both absent (compare Rows 2 and 14 of Table [1](#T1){ref-type="table"}), and reduces `Abeta` from 13 to 7 with `estrogen` absent but `CVD` present (compare Rows 1 and 17 of Table [2](#T2){ref-type="table"}), is also due to a threshold effect, specifically a failure to cross the `OS` threshold.

Under conditions in which `estrogen` is absent but `CVD` is present, and `ERalphaAg` is administered in combination either with `NSAID` or `HIFblock`, neither the `OS` nor the `cytokine` thresholds will be crossed, and `Abeta` will be held at the relatively low level of 5 (Rows 18 and 19 in Table [2](#T2){ref-type="table"}). Under these same conditions, administration of `ERalphaAg` in combination with both `NSAID` and `HIFblock` will further reduce `Abeta` to 4 (Row 21 in Table [2](#T2){ref-type="table"}). Administration of `caspBlock` confers no additional benefit (Row 22 of Table [2](#T2){ref-type="table"}). These results suggest that, under conditions of low estrogen and incipient CVD, administration of an ERα agonist alone or combined with an NSAID-class drug that promotes PPAR expression and/or a compound that blocks HIF, would be effective in lowering Aβ, but that a compound that blocks caspase-3 activation would confer no additional benefit.

While `ERalphaAg` alone, and especially in combination with `NSAID` and `HIFblock`, produces a substantial reduction in `Abeta` when `estrogen` is absent but `CVD` is present, administration of `estrogen` itself is even more effective. Administration of `estrogen` in the presence of `CVD` lowers `BACEmRNA` from 9 to 7, `BACE` from 13 to 10, and `Abeta` from 13 to 4 (compare Rows 1 and 23 of Table [2](#T2){ref-type="table"}). This dramatic lowering of `Abeta` is a compound threshold effect, since administration of `estrogen` in the presence of `CVD` lowers `Abeta` below the thresholds of activation of both `OS` and `cytokine`. Under these conditions, administration of `NSAID` or `HIFblock` results in further reduction of `BACEmRNA`, `BACE`, and `Abeta` each by 1 (Rows 24 and 25 of Table [2](#T2){ref-type="table"}). Because `estrogen` both prevents `OS` and promotes `seladin1` it is able to suppress `caspase3`, so administration of `caspBlock` provides no additional benefit in the presence of both `estrogen` and `CVD` (Row 26 in Table [2](#T2){ref-type="table"}). When `Abeta` is below both the `OS` and `cytokine` thresholds the effects of `NSAID` and `HIFblock` are additive, rather than synergistic, so that administration of `NSAID` and `HIFblock` together results in a further reduction of `BACEmRNA`, `BACE`, and `Abeta` each by 1 (Row 27 of Table [2](#T2){ref-type="table"}). As expected, `caspBlock` provides no additional benefit in terms of `Abeta` reduction in the presence of `estrogen`, even if administered in combination with `NSAID` and `HIFblock` (Rows 26 and 28 of Table [2](#T2){ref-type="table"}). In the presence of `CVD`, the combined administration of `estrogen`, `NSAID`, and `HIFblock` brings `Abeta` from the `AD`-inducing level of 13 all the way back to the normative level of 2 (compare Rows 1 and 27 of Table [2](#T2){ref-type="table"}). These modeling results suggest the possibility that, under conditions of very low estrogen and incipient CVD, the level of Aβ could be brought back to normal with a combination of an NSAID-class drug that promotes PPAR expression and a compound that blocks HIF, in conjunction with estrogen itself.

ERα agonists may be less effective than estrogen itself in lowering Aβ
----------------------------------------------------------------------

Using `NSAID` and `HIFblock` in the presence of `CVD`, `ERalphaAg` can reduce `Abeta` to 4, but `estrogen` itself can reduce `Abeta` all the way back to the normative level of 2 (compare Rows 21 and 27 of Table [2](#T2){ref-type="table"}). Although `estrogen` by itself can prevent `cytokine` activation in the presence of `CVD`, `ERalphaAg` can also prevent `cytokine` activation in combination with `NSAID` and `HIFblock` (note that `estrogen` or `ERalphaAg` alone can prevent `OS` as shown in Rows 17 and 23 of Table [2](#T2){ref-type="table"}). Furthermore, `apoE` reaches level 2 with `estrogen` but reaches level 3 with `ERalphaAg`, so `ERalphaAg` provides a benefit over `estrogen` itself in terms of `apoE`. Why then is `estrogen` able to reduce `Abeta` even further than `ERalphaAg`? Temporal-logic analysis can be used to answer that question in the model.

Temporal-logic analysis begins by defining properties of interest, and then checking the value of those properties alone or combined into propositions (see [Materials and Methods](#s3){ref-type="sec"}). Some properties that are useful for this analysis are: `ERaACT`, `ERbACT`, `PKCeq1`, and `AbEQ2` (other properties also used have similar nomenclature). The properties `ERaACT` and `ERbACT` are true when `ERalpha` or `ERbeta`, respectively, are activated by `estrogen`. The properties `PKCeq1` and `AbEQ2` are true when `PKCalpha` is 1 or when `Abeta` is 2, respectively. The value of these (and other) properties alone or combined into propositions can be checked under specific sets of conditions. To determine why `estrogen`, in combination with `NSAID` and `HIFblock`, can bring `Abeta` to level 2 in the presence of `CVD`, the analysis takes place under conditions in which `estrogen`, `NSAID`, `HIFblock`, and `CVD` are all present.

In the Maude specification `ALZHEIMERE`, which specifies the estrogen-Aβ model, `estrogen` activates `ERalpha` and `ERbeta`, and it also brings `PKCalpha` to level 1. Because all three of these interactions are specified as rules, temporal-logic analysis can be used to explore the consequences of these interactions in all possible orders of occurrence. Some results of the temporal-logic analysis are shown in Table [3](#T3){ref-type="table"}. To begin, temporal-logic analysis is used to check the value of the proposition `ERaACT` ⇒ `AbEQ2` (where ⇒ is the logical connector "implies"). This proposition states that `Abeta` is at level 2 only if `ERalpha` is activated. This is false under the conditions of the analysis (Row 1 of Table [3](#T3){ref-type="table"}), meaning that other actions of `estrogen` besides activation of `ERalpha` are necessary to keep `Abeta` at level 2.

###### 

**Using temporal-logic to check the model in the presence of `CVD` when `estrogen`, `NSAID`, and `HIFblock`, but not `caspBlock`, are available**.

  \#   Proposition                                                                         Value
  ---- ----------------------------------------------------------------------------------- -------
  1    Activation of ERalpha implies Abeta equals two                                      False
  2    Activation of ERalpha and ERbeta implies Abeta equals two                           False
  3    Activation of ERalpha, and PKCalpha equals one, imply Abeta equals two              False
  4    Activation of ERbeta, and PKCalpha equals one, imply Abeta equals two               False
  5    Activation of ERalpha and ERbeta, and PKCalpha equals one, imply Abeta equals two   True
  6    Activation of ERalpha or ERbeta implies PKCalpha equals one                         False
  7    PKCalpha does not equal one until estrogen equals one                               True
  8    PKCalpha equals one implies Abeta equals two                                        False
  9    Activation of ERalpha implies NEP equals three                                      False
  10   Activation of ERalpha and ERbeta implies NEP equals three                           True
  11   NEP equals three implies Abeta equals two                                           False
  12   PKCalpha equals one and NEP equals three imply Abeta equals two                     True
  13   Abeta does not equal two until PKCalpha equals one and NEP equals three             True

*Each row lists a proposition and its logical value (true or false). The row numbers appear in the leftmost column*.

The first five rows in Table [3](#T3){ref-type="table"} lists a set of propositions and their values that ends with the proposition `(ERaACT` ∧ `ERbACT` ∧ `PKCeq1)` ⇒ `AbEQ2` (where ∧ is the logical connector "and"). This proposition states that `Abeta` is at level 2 only if `ERalpha` and `ERbeta` are activated and `PKCalpha` is at level 1. This statement is true but the previous propositions, whose antecedents are a conjunction (i.e., joined by "and") of only two of the three properties in this antecedent, are all false (Rows 2 through 5 of Table [3](#T3){ref-type="table"}). This means that `Abeta` will stay at level 2 only if `estrogen` activates `ERalpha` and `ERbeta` and brings `PKCalpha` to level 1 (i.e., all three of the functions of `estrogen` in the model are necessary).

Because PKCα activity is increased by estrogen directly (see [Materials and Methods](#s3){ref-type="sec"}), it is useful to make sure that `PKCalpha` activity cannot be increased indirectly via `ERalpha` or `ERbeta` activation in the model. The proposition `(ERaACT` ∨ `ERbACT)` ⇒ `PKCeq1` (where ∨ is the logical connector "or") is false, meaning that neither `ERaACT` nor `ERbACT` activation is sufficient to raise the level of `PKCalpha` to 1 (Row 6 of Table [3](#T3){ref-type="table"}). The proposition ∼ `PKCeq1 U estEQ1` states that `PKCalpha` is not 1 until estrogen is present (`estEQ1` is the property that `estrogen` is 1, and ∼ and `U` are the temporal-logic connectors "not" and "until," respectively). This proposition is true, and the two propositions together prove `estrogen` raises the level of `PKCalpha`, but not via activation of `ERalpha` or `ERbeta` (Rows 6 and 7 of Table [3](#T3){ref-type="table"}).

The temporal-logic analysis so far reveals an important difference between administration of `estrogen` and `ERalphaAg`: `estrogen`, but not `ERalphaAg`, raises the activity level of `PKCalpha`. Perhaps it is the increase in `PKCalpha` activity that allows `estrogen` to keep `Abeta` at the normative level 2 while `ERalphaAg` fails to do so? This question can be answered by checking the value of the proposition `PKCeq1` ⇒ `AbEQ2`, which states that `Abeta` is 2 only if `PKCalpha` is 1. This proposition is false, meaning that `PKCalpha` at level 1 is not sufficient to keep `Abeta` at level 2 (Row 8 of Table [3](#T3){ref-type="table"}).

Another difference between the effects of administration of `estrogen` and `ERalphaAg` concerns `NEP`. Expression of the enzyme NEP, which degrades Aβ, is upregulated by activation of ERα or ERβ, and upregulation by both receptors is additive (see [Materials and Methods](#s3){ref-type="sec"}). In the model, `estrogen`, which activates both `ERalpha` and `ERbeta`, raises `NEP` to 3, and it is useful to check to ensure that `ERalphaAg` cannot raise `NEP` to 3 by itself. The proposition `ERaACT` ⇒ `NEPeq3` (where `NEPeq3`is the property that `NEP` is at level 3) is false (Row 9 of Table [3](#T3){ref-type="table"}). This means that activation of `ERalpha` alone is not sufficient to raise `NEP` to level 3. The proposition `(ERaACT` ∧ `ERbACT)` ⇒ `NEPeq3` is true (Row 10 of Table [3](#T3){ref-type="table"}), meaning that `NEP` reaches level 3 only if both `ERalpha` and `ERbeta` are activated. Thus, `estrogen` raises `NEP` to level 3 because it activates both `ERalpha` and `ERbeta`.

Perhaps it is this increase in `NEP` expression that allows `estrogen` to keep `Abeta` at the normative level 2 while `ERalphaAg` fails to do so? This question can be answered by checking the proposition `NEPeq3` ⇒ `AbEQ2`, which states that `Abeta` is 2 only if `NEP` is 3. This proposition is false (Row 11 of Table [3](#T3){ref-type="table"}), meaning that `NEP` at level 3 is not sufficient to keep `Abeta` at level 2. This leads to the question of whether the increases due to `estrogen` of `PKCalpha` and `NEP` are both necessary to keep `Abeta` at its normative level in the presence of `CVD`. This question can be answered by checking the values of two further propositions. The proposition `(PKCeq1` ∧ `NEPeq3)` ⇒ `AbEQ2` is true, meaning that `Abeta` stays at level 2 only if `PKCalpha` is 1 and `NEP` is 3. The proposition ∼ `AbEQ2 U (PKCeq1` ∧ `NEPeq3)` is also true, meaning that `Abeta` is not 2 until `PKCalpha` is 1 and `NEP` is 3 (Rows 12 and 13 of Table [3](#T3){ref-type="table"}). These two propositions together prove that `Abeta` is not at level 2 unless `PKCalpha` is at level 1 and `NEP` is at level 3. The temporal-logic analysis in this subsection suggests that, under conditions of low estrogen and incipient CVD, and with co-administration of an NSAID that promotes PPAR expression and a compound that blocks HIF, administration of estrogen itself would be more effective in lowering Aβ than administration of an ERα agonist.

Discussion {#s1}
==========

The main finding of the simulations and analysis presented in Results is that, under conditions of very low estrogen and incipient CVD, the level of Aβ could be reduced, possibly to normative levels, with a combination of an NSAID that promotes PPAR expression, a compound that blocks HIF, and estrogen itself. The model suggests that estrogen would provide the main benefit, reducing Aβ directly (e.g., by enhancing NEP expression) and indirectly by reducing inflammation and OS (e.g., by enhancing SOD expression), thereby disrupting pathological processes that contribute to Aβ accumulation. With estrogen itself providing the main benefit, an NSAID and a HIF-blocker can each provide a small additional benefit, and these two benefits are additive in combination. The idea of combination estrogen/NSAID/HIF-blocker therapy for the treatment of AD in post-menopausal women is plausible.

The usage of estrogen and its derivatives for hormone replacement therapy is widespread but its benefits are still hotly debated (Barlow, [@B7]; Shifren and Schiff, [@B67]; Daniel, [@B17]; Marjoribanks et al., [@B52]; Moyer and On Behalf of the U.S. Preventive Services Task Force, [@B53]; Nelson et al., [@B55]). A consensus seeming to emerge is that estrogen replacement therapy may provide some neuroprotection if initiated soon after menopause.

The usage of estrogen is dwarfed by that of NSAIDs, which are among the most commonly used over-the-counter drugs. While epidemiological studies show that NSAIDs reduce AD risk, clinical trials testing NSAID efficacy in AD patients have not yielded positive results (Heneka et al., [@B34]). However, available evidence does not rule out the possibility that NSAIDs could be effective in combination with estrogen. NSAIDs potentially may reduce Aβ via several mechanisms including upregulation of PPAR expression (Sastre et al., [@B62]), and modulation of γ-secretase activity in such a way that APP processing by γ-secretase is reduced more than processing by γ-secretase of its other substrates (De Strooper et al., [@B21]). The model represents only the PPAR-upregulating function of NSAIDs and suggests that it may augment PPAR upregulation due to estrogen, thereby providing additional benefit. The γ-secretase-modulating role of NSAIDs could also provide some benefit, but that was not explored in this model.

Compounds exist that block HIF. One such is cilnidipine, which is also a calcium-channel blocker but it blocks HIF synthesis independently of its effects on ion channels (Oda et al., [@B58]). The discovery that cilnidipine blocks HIF synthesis raises the possibility that pharmaceuticals that specifically block HIF could be developed. The model suggests that such drugs would be useful for the prevention of AD, especially in combination with estrogen and NSAIDs. Compounds also exist that block the activation of caspase-3 (Dave et al., [@B18]), but the model suggests that blocking caspase-3 would be ineffective if co-administered with estrogen because estrogen already prevents caspase-3 activation directly, by increasing seladin-1 expression, and indirectly by reducing OS in the model.

The model also suggests that, in terms of reducing the level of Aβ, agonists of ERα would be substantially more effective than agonists of ERβ. Among the differential effects of ERα or ERβ activation, two are represented in the model: ERα activation increases seladin-1 expression but ERβ activation does not (Benvenuti et al., [@B8]), and ERα activation increases apoE expression while ERβ activation suppresses it (Wang et al., [@B86]). The three most common apoE isoforms are apoE2, apoE3, and apoE4, and the apoE4 isoform is associated with increased risk of AD (Saunders, [@B63]). These findings suggest that administration of an ERβ agonist could be the preferred treatment in carriers of the apoE4 allele (Wang et al., [@B86]). Otherwise, the model suggests that ERα should produce a dramatic reduction in Aβ by preventing it from triggering OS, which leads to further Aβ accumulation. The model also suggests that estrogen itself would be more effective than ERα agonists because estrogen, by activating both ERα and ERβ, brings NEP to a higher level than specific agonists of either receptor could do (Liang et al., [@B49]), and because estrogen directly activates PKCα (Alzamora et al., [@B3]), which in turn shifts APP processing away from the Aβ pathway by activating α-secretase (Cisse et al., [@B15]). The combined effects of estrogen alone prevent OS and also prevent the activation of cytokines.

In pulling many strands of data together, the model provides potential new insights into the contribution that estrogen makes to Aβ regulation. Its two main predictions are that, under conditions of low estrogen and incipient CVD, estrogen should reduce Aβ levels more than specific agonists either of ERα or ERβ, and NSAIDs and/or compounds that block HIF should provide additional benefit in combination with estrogen. However, any of the input/output configurations presented in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} could be taken as predictions of the model. These predictions could be tested experimentally using essentially the same *in vitro* and *in vivo* (mainly mouse) methods that were used to generate the data represented in the model. The results could be used to verify or correct the model, and verified predictions would provide avenues for development of new pharmacological strategies for the prevention and treatment of AD.

The model aggregates much of the current literature on Aβ regulation and the contribution of estrogen, but it is clear that the model could be expanded to include many more relevant interactions. Even still, at about 80 molecular interactions, the computational model could potentially generate a wide range of predictions, and far more than could be generated without it. The model demonstrates how declarative programming can be used to represent, simulate, and analyze large amounts of data on complex neurodegenerative processes and to generate experimentally testable predictions, and it stakes its claim as the starting point of a process in which model predictions are tested, the results are used to correct and extend the model, more predictions are generated and tested, and the process continues. The result is a model of ever increasing accuracy and explanatory power that provides ever more insight into the complex system of molecular interactions that underlie AD.

The model also illustrates the power of computation in representing and reasoning about complex neurodegenerative diseases, and clearly shows how it could be used to derive hypotheses concerning the potential benefits of multi-drug therapies. The approach is consistent with the general idea that complex problems require complex solutions, and that multifactorial disease processes such as neurodegenerative diseases should be combatted simultaneously on multiple fronts. Computational modeling of neurodegenerative disease processes using declarative programming provides a powerful methodology to aggregate data and search for potentially effective drug combinations. Support for expanding the model computationally and testing it experimentally should be provided. The current model is a call to arms.
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